JPS645576B2 - - Google Patents
Info
- Publication number
- JPS645576B2 JPS645576B2 JP57031467A JP3146782A JPS645576B2 JP S645576 B2 JPS645576 B2 JP S645576B2 JP 57031467 A JP57031467 A JP 57031467A JP 3146782 A JP3146782 A JP 3146782A JP S645576 B2 JPS645576 B2 JP S645576B2
- Authority
- JP
- Japan
- Prior art keywords
- fibrinolytic
- registered trademark
- earthworms
- extract
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000003480 fibrinolytic effect Effects 0.000 claims description 15
- 241001233061 earthworms Species 0.000 claims description 14
- 239000013543 active substance Substances 0.000 claims description 13
- 239000003125 aqueous solvent Substances 0.000 claims description 13
- 239000003527 fibrinolytic agent Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 239000003463 adsorbent Substances 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 239000003495 polar organic solvent Substances 0.000 claims description 5
- AELCINSCMGFISI-DTWKUNHWSA-N (1R,2S)-tranylcypromine Chemical compound N[C@@H]1C[C@H]1C1=CC=CC=C1 AELCINSCMGFISI-DTWKUNHWSA-N 0.000 claims description 3
- 108010039627 Aprotinin Proteins 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 101710162629 Trypsin inhibitor Proteins 0.000 claims description 3
- 229940122618 Trypsin inhibitor Drugs 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 238000002523 gelfiltration Methods 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 238000004255 ion exchange chromatography Methods 0.000 claims description 3
- 230000033885 plasminogen activation Effects 0.000 claims description 3
- 238000005185 salting out Methods 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 229940108519 trasylol Drugs 0.000 claims description 3
- 239000002753 trypsin inhibitor Substances 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 230000001471 fibrinogenolytic effect Effects 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000361919 Metaphire sieboldi Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229920001429 chelating resin Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 2
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010023197 Streptokinase Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- BIGPRXCJEDHCLP-UHFFFAOYSA-N ammonium bisulfate Chemical compound [NH4+].OS([O-])(=O)=O BIGPRXCJEDHCLP-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 229960005202 streptokinase Drugs 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- DPEYHNFHDIXMNV-UHFFFAOYSA-N (9-amino-3-bicyclo[3.3.1]nonanyl)-(4-benzyl-5-methyl-1,4-diazepan-1-yl)methanone dihydrochloride Chemical compound Cl.Cl.CC1CCN(CCN1Cc1ccccc1)C(=O)C1CC2CCCC(C1)C2N DPEYHNFHDIXMNV-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- -1 hypothermics Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57031467A JPS58148824A (ja) | 1982-02-27 | 1982-02-27 | 線溶活性物質の製造法 |
CA000422034A CA1198672A (en) | 1982-02-27 | 1983-02-21 | Fibrinolytically active agent and a method for the preparation thereof |
FR8303165A FR2522266B1 (fr) | 1982-02-27 | 1983-02-25 | Procede de preparation d'un agent fibrinolytiquement actif et agent obtenu |
GB08305359A GB2116565B (en) | 1982-02-27 | 1983-02-25 | A fibrinolytically active agent and a method for the preparation thereof |
IT47795/83A IT1197586B (it) | 1982-02-27 | 1983-02-25 | Agente fibrinoliticamente attivo e metodo per la sua preparazione |
DE19833306944 DE3306944A1 (de) | 1982-02-27 | 1983-02-28 | Fibrinolytisch aktives mittel und verfahren zu seiner herstellung |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57031467A JPS58148824A (ja) | 1982-02-27 | 1982-02-27 | 線溶活性物質の製造法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS58148824A JPS58148824A (ja) | 1983-09-05 |
JPS645576B2 true JPS645576B2 (sv) | 1989-01-31 |
Family
ID=12332056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP57031467A Granted JPS58148824A (ja) | 1982-02-27 | 1982-02-27 | 線溶活性物質の製造法 |
Country Status (6)
Country | Link |
---|---|
JP (1) | JPS58148824A (sv) |
CA (1) | CA1198672A (sv) |
DE (1) | DE3306944A1 (sv) |
FR (1) | FR2522266B1 (sv) |
GB (1) | GB2116565B (sv) |
IT (1) | IT1197586B (sv) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1629383A (en) * | 1982-10-02 | 1984-04-05 | Amano Seiyaku K.K. | Earthworm tissue protease thrombolytic agents |
DE3519736C2 (de) * | 1985-06-01 | 1995-11-16 | Haeusler Gerd | Mittel zur Behandlung von Rheuma und Polyarthritis |
US5024844A (en) * | 1987-08-18 | 1991-06-18 | Eimei Company, Ltd. | Process for the production of dried earthworm powder and antihyperlipemic, antidiabetic, antihypertensive and antihypotensive preparations containing dried earthworm powder as active ingredient |
KR900012617A (ko) * | 1987-10-28 | 1990-09-01 | 요오이찌 이시이 | 혈전증 치료제 및 그 제조방법 |
IT1230719B (it) * | 1988-04-19 | 1991-10-29 | Eimei Co Ltd | Procedimento per la produzione di polvere di lombrichi secca e preparazioni anti iperlipemiche, anti diabetiche, anti ipertensive ed anti ipotensive contenenti, come ingrediente attivo, polvere secca di lombrichi. |
US5186944A (en) * | 1989-02-15 | 1993-02-16 | Eimei Company Ltd. | Therapeutic medicament for thrombosis |
JP2006096673A (ja) * | 2004-09-28 | 2006-04-13 | Mihara Lr Kenkyusho:Kk | ミミズ製品の製造方法 |
JP2009143845A (ja) * | 2007-12-14 | 2009-07-02 | Mihara Lr Kenkyusho:Kk | ミミズ抽出液の製造方法及びミミズ乾燥粉末の製造方法 |
EP2255819A1 (en) * | 2009-05-26 | 2010-12-01 | Inmobiliaria Algeciras Ltda | Extract of annelid and use thereof for the regeneration of the skin |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1629383A (en) * | 1982-10-02 | 1984-04-05 | Amano Seiyaku K.K. | Earthworm tissue protease thrombolytic agents |
-
1982
- 1982-02-27 JP JP57031467A patent/JPS58148824A/ja active Granted
-
1983
- 1983-02-21 CA CA000422034A patent/CA1198672A/en not_active Expired
- 1983-02-25 FR FR8303165A patent/FR2522266B1/fr not_active Expired
- 1983-02-25 IT IT47795/83A patent/IT1197586B/it active
- 1983-02-25 GB GB08305359A patent/GB2116565B/en not_active Expired
- 1983-02-28 DE DE19833306944 patent/DE3306944A1/de active Granted
Also Published As
Publication number | Publication date |
---|---|
FR2522266B1 (fr) | 1987-07-31 |
IT1197586B (it) | 1988-12-06 |
GB2116565B (en) | 1985-02-27 |
GB8305359D0 (en) | 1983-03-30 |
FR2522266A1 (fr) | 1983-09-02 |
DE3306944C2 (sv) | 1989-04-13 |
IT8347795A0 (it) | 1983-02-25 |
CA1198672A (en) | 1985-12-31 |
JPS58148824A (ja) | 1983-09-05 |
DE3306944A1 (de) | 1983-09-15 |
GB2116565A (en) | 1983-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4568545A (en) | Thrombolytic agent | |
JPH01308292A (ja) | ガングリオシド誘導体の製造法 | |
JPS62174023A (ja) | 抗血液凝固物質、その製法及びそれを有効成分とする抗血液凝固剤 | |
US2662046A (en) | Parenteral amino acid solution | |
JPS645576B2 (sv) | ||
JP2532535B2 (ja) | 組織タンパクpp4含有医薬 | |
DE2459915C3 (de) | Aktive Verbindung des Plasminogen- Typs, Verfahren zu ihrer Reinigung und ihre Verwendung | |
JPS5944286B2 (ja) | 牛トロンビンの精製法 | |
US4106992A (en) | Purification of urokinase | |
JPH0753667B2 (ja) | 骨髄移植療法補助剤 | |
JPS6130527A (ja) | 血栓溶解剤 | |
US4029767A (en) | Pharmaceutical compositions of stable urokinase-heparin complexes and methods for use thereof | |
JPS61189228A (ja) | 血液凝固第8因子製剤の製法 | |
US4479937A (en) | Process of treating inflammation with human urinary thiol protease inhibitor | |
US3627642A (en) | Lysozyme salts | |
JPS597695B2 (ja) | 免疫制御作用を有するペプタイド製剤 | |
US2794800A (en) | Preparation of antitryptic substance from soybean | |
JPS5822445B2 (ja) | 安定な固体の人血漿コリンエステラ−ゼ製剤の製法 | |
JPS61109727A (ja) | ウロキナーゼの殺菌方法 | |
Barton-Wright et al. | Isolation from liver of new factors essential for the growth of Lactobacillus helveticus and Streptococcus lactis R | |
EP0230956B1 (de) | Verfahren zur Gewinnung und Herstellung eines pasteurisierten Präparates von alpha2-Antiplasmin | |
JPS58172321A (ja) | 桃の種子から得られる生物活性蛋白質pr−a及びpr−b並びにその製法 | |
JPS608226A (ja) | 低分子蛋白質を有効成分とする制ガン剤 | |
DE2246969A1 (de) | Verfahren zur herstellung von urokinase | |
HUCK | THE BIOELECTRIC RHYTHM IN GENERAL TETANUS OF THE RABBIT |